Gain Therapeutics (GANX) Competitors $1.68 +0.08 (+5.00%) Closing price 04:00 PM EasternExtended Trading$1.69 +0.01 (+0.83%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. ACB, NGNE, TVRD, BTMD, SLRN, TVGN, CGC, PRQR, NBTX, and YMABShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), biote (BTMD), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors Aurora Cannabis Neurogene Tvardi Therapeutics biote Acelyrin Semper Paratus Acquisition Canopy Growth ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics Aurora Cannabis (NASDAQ:ACB) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more risk & volatility, ACB or GANX? Aurora Cannabis has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Do insiders & institutionals believe in ACB or GANX? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate ACB or GANX? Gain Therapeutics has a consensus target price of $8.20, indicating a potential upside of 388.10%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is ACB or GANX more profitable? Aurora Cannabis has a net margin of 1.32% compared to Gain Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis1.32% 0.13% 0.10% Gain Therapeutics N/A -247.55%-146.06% Does the media refer more to ACB or GANX? In the previous week, Aurora Cannabis and Aurora Cannabis both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 0.53 beat Aurora Cannabis' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ACB or GANX? Aurora Cannabis has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.04$1.63M$0.1141.45Gain Therapeutics$50K1,006.32-$20.41M-$0.86-1.95 SummaryAurora Cannabis beats Gain Therapeutics on 11 of the 16 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.32M$2.37B$5.46B$8.92BDividend YieldN/A1.78%5.24%4.04%P/E Ratio-1.958.9127.0120.12Price / Sales1,006.32499.49380.1493.35Price / CashN/A21.7726.2128.59Price / Book6.004.537.995.57Net Income-$20.41M$31.26M$3.16B$248.40M7 Day Performance7.01%5.57%3.69%6.04%1 Month Performance-12.50%5.48%2.91%7.69%1 Year Performance50.00%1.14%34.30%20.97% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics3.0439 of 5 stars$1.68+5.0%$8.20+388.1%+33.3%$50.32M$50K-1.9520Positive NewsACBAurora Cannabis0.099 of 5 stars$4.24+2.2%N/A-8.1%$233.29M$246.72M38.551,130NGNENeurogene3.7905 of 5 stars$14.95-7.5%$46.17+208.8%-42.9%$230.48M$930K-3.4490TVRDTvardi TherapeuticsN/A$23.33-5.2%$71.50+206.5%N/A$230.37M$7.14M0.0080BTMDbiote3.0952 of 5 stars$4.02-4.3%$8.00+99.0%-46.0%$229.78M$197.19M6.59194News CoveragePositive NewsSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition3.9649 of 5 stars$1.25+0.8%$10.00+700.0%+71.4%$228.03MN/A0.003CGCCanopy Growth2.8393 of 5 stars$1.22flat$2.00+63.9%-81.1%$224.32M$225.65M-0.303,150PRQRProQR Therapeutics2.1135 of 5 stars$2.04flat$8.00+292.2%+25.9%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix1.6904 of 5 stars$4.73+4.4%$8.00+69.1%-13.1%$213.34M$39.18M0.00100News CoveragePositive NewsGap UpYMABY-mAbs Therapeutics3.15 of 5 stars$4.51-4.0%$15.60+245.9%-63.0%$212.84M$88.66M-7.05150 Related Companies and Tools Related Companies Aurora Cannabis Alternatives Neurogene Alternatives Tvardi Therapeutics Alternatives biote Alternatives Acelyrin Alternatives Semper Paratus Acquisition Alternatives Canopy Growth Alternatives ProQR Therapeutics Alternatives Nanobiotix Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts